{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T17:08:26Z","timestamp":1789837706266,"version":"4.0.1"},"reference-count":178,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T00:00:00Z","timestamp":1789776000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Gliomas, particularly glioblastoma, are characterized by profound molecular and cellular heterogeneity that drives tumor progression, therapeutic resistance, and poor clinical outcomes. Increasing evidence indicates that epigenetic deregulation, extending beyond genetic alterations, plays a central role in glioma initiation, evolution, and treatment response. This review summarizes current advances in the epigenetic landscape of adult gliomas with particular emphasis on the interplay between DNA methylation, histone modifications, chromatin remodeling and their contributions to molecular heterogeneity and precision neuro-oncology. We discuss key epigenetic mechanisms, including global DNA hypomethylation, promoter CpG island hypermethylation, histone acetylation and methylation and their effects on genome stability, transcriptional regulation, stemness, immune modulation, metabolic reprogramming, and therapeutic resistance. Clinically relevant biomarkers, including O6-methylguanine-DNA methyltransferase promoter methylation and the glioma CpG island methylator phenotype, are highlighted alongside emerging therapeutic targets such as histone deacetylases, Enhancer of Zeste Homologue 2, G9a, and protein arginine methyltransferase 5. We further examine the impact of spatial and temporal epigenetic heterogeneity on biomarker interpretation and treatment selection, as well as recent advances in methylation-based tumor classification. Collectively, this review highlights epigenetic deregulation as both a fundamental driver of adult glioma biology and a promising foundation for precision oncology.<\/jats:p>","DOI":"10.1093\/jnen\/nlag096","type":"journal-article","created":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T11:38:46Z","timestamp":1786448326000},"source":"Crossref","is-referenced-by-count":0,"title":["Epigenetic deregulation in adult gliomas: A\u00a0key driver of molecular heterogeneity and precision oncology"],"prefix":"10.1093","author":[{"given":"Elifcan","family":"Gezer","sequence":"first","affiliation":[{"name":"Institute of Graduate Studies in Health Sciences, Istanbul University , Istanbul,","place":["T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7035-3704","authenticated-orcid":false,"given":"Hamed","family":"Charkhian","sequence":"additional","affiliation":[{"name":"Institute of Graduate Studies in Health Sciences, Istanbul University , Istanbul,","place":["T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8023-3223","authenticated-orcid":false,"given":"Seref Bugra","family":"Tuncer","sequence":"additional","affiliation":[{"name":"Department of Cancer Genetics, Oncology Institute, Istanbul University , Istanbul,","place":["T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,9,19]]},"reference":[{"key":"2026091912541429400_nlag096-B1","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/S1474-4422(18)30468-X","article-title":"Global, regional, and national burden of brain and other CNS cancer, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"18","author":"Patel","year":"2019","journal-title":"Lancet Neurol"},{"key":"2026091912541429400_nlag096-B2","doi-asserted-by":"publisher","first-page":"iv1","DOI":"10.1093\/neuonc\/noaf194","article-title":"CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2018-2022","volume":"27","author":"Price","year":"2025","journal-title":"Neuro Oncol"},{"key":"2026091912541429400_nlag096-B3","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification of tumors of the central nervous system: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol"},{"key":"2026091912541429400_nlag096-B4","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med"},{"key":"2026091912541429400_nlag096-B5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/nrdp.2015.17","article-title":"Glioma","volume":"1","author":"Weller","year":"2015","journal-title":"Nat Rev Dis Primer"},{"key":"2026091912541429400_nlag096-B6","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1126\/science.1254257","article-title":"Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma","volume":"344","author":"Patel","year":"2014","journal-title":"Science"},{"key":"2026091912541429400_nlag096-B7","doi-asserted-by":"publisher","first-page":"4009","DOI":"10.1073\/pnas.1219747110","article-title":"Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics","volume":"110","author":"Sottoriva","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026091912541429400_nlag096-B8","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.cell.2015.12.028","article-title":"Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma","volume":"164","author":"Ceccarelli","year":"2016","journal-title":"Cell"},{"key":"2026091912541429400_nlag096-B9","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/nature26000","article-title":"DNA methylation-based classification of central nervous system tumours","volume":"555","author":"Capper","year":"2018","journal-title":"Nature"},{"key":"2026091912541429400_nlag096-B10","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.4161\/cbt.7.9.6992","article-title":"Epigenetic changes in gliomas","volume":"7","author":"Burgess","year":"2008","journal-title":"Cancer Biol Ther"},{"key":"2026091912541429400_nlag096-B11","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.3390\/cancers15041342","article-title":"DNA methylation and histone modification in low-grade gliomas: current understanding and potential clinical targets","volume":"15","author":"Ozair","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2026091912541429400_nlag096-B12","doi-asserted-by":"publisher","first-page":"2472","DOI":"10.3390\/ijms16022472","article-title":"Promoter hypermethylation of tumour suppressor genes as potential biomarkers in colorectal cancer","volume":"16","author":"Ng","year":"2015","journal-title":"Int J Mol Sci"},{"key":"2026091912541429400_nlag096-B13","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1186\/1471-2164-11-701","article-title":"DNA methylation in glioblastoma: impact on gene expression and clinical outcome","volume":"11","author":"Etcheverry","year":"2010","journal-title":"BMC Genomics"},{"key":"2026091912541429400_nlag096-B14","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1093\/neuonc\/noz011","article-title":"Intratumor DNA methylation heterogeneity in glioblastoma: implications for DNA methylation-based classification","volume":"21","author":"Wenger","year":"2019","journal-title":"Neuro Oncol"},{"key":"2026091912541429400_nlag096-B15","doi-asserted-by":"publisher","first-page":"408","DOI":"10.3389\/fnmol.2018.00408","article-title":"Potential epigenetic-based therapeutic targets for glioma","volume":"11","author":"Zang","year":"2018","journal-title":"Front Mol Neurosci"},{"key":"2026091912541429400_nlag096-B16","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s13148-016-0237-y","article-title":"A clinical-molecular update on azanucleoside-based therapy for the treatment of hematologic cancers","volume":"8","author":"Diesch","year":"2016","journal-title":"Clin Epigenetics"},{"key":"2026091912541429400_nlag096-B17","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s12672-024-00919-z","article-title":"The prevalence of ADSL (rs3788579) and CYP1A2 (rs17861162) polymorphisms in female breast cancer patients in North-West Iran","volume":"15","author":"Valizadeh Osalo","year":"2024","journal-title":"Discov Oncol"},{"key":"2026091912541429400_nlag096-B18","first-page":"1","article-title":"The genomic landscape of pheochromocytoma and paraganglioma: from molecular classification to precision therapy","volume":"1","author":"Gultaslar","year":"2026","journal-title":"J Genom Precis Med"},{"key":"2026091912541429400_nlag096-B19","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.ccr.2009.12.020","article-title":"Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1","volume":"17","author":"Verhaak","year":"2010","journal-title":"Cancer Cell"},{"key":"2026091912541429400_nlag096-B20","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.ccell.2017.06.003","article-title":"Tumor evolution of glioma-intrinsic gene expression subtypes associates with immunological changes in the microenvironment","volume":"32","author":"Wang","year":"2017","journal-title":"Cancer Cell"},{"key":"2026091912541429400_nlag096-B21","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.cell.2019.06.024","article-title":"An integrative model of cellular states, plasticity, and genetics for glioblastoma","volume":"178","author":"Neftel","year":"2019","journal-title":"Cell"},{"key":"2026091912541429400_nlag096-B22","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/j.ccr.2010.03.017","article-title":"Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma","volume":"17","author":"Noushmehr","year":"2010","journal-title":"Cancer Cell"},{"key":"2026091912541429400_nlag096-B23","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ccr.2010.12.014","article-title":"Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of \u03b1-ketoglutarate-dependent dioxygenases","volume":"19","author":"Xu","year":"2011","journal-title":"Cancer Cell"},{"key":"2026091912541429400_nlag096-B24","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1056\/NEJMoa1407279","article-title":"Glioma groups based on 1p\/19q, IDH, and TERT promoter mutations in tumors","volume":"372","author":"Eckel-Passow","year":"2015","journal-title":"N Engl J Med"},{"key":"2026091912541429400_nlag096-B25","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1007\/s00701-022-05301-y","article-title":"The WHO 2021 Classification of Central Nervous System tumours: a practical update on what neurosurgeons need to know\u2014a minireview","volume":"164","author":"Torp","year":"2022","journal-title":"Acta Neurochir (Wien)"},{"key":"2026091912541429400_nlag096-B26","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s00401-007-0243-4","article-title":"The 2007 WHO classification of tumours of the central nervous system","volume":"114","author":"Louis","year":"2007","journal-title":"Acta Neuropathol"},{"key":"2026091912541429400_nlag096-B27","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","article-title":"The 2016 World Health Organization classification of tumors of the central nervous system: a summary","volume":"131","author":"Louis","year":"2016","journal-title":"Acta Neuropathol"},{"key":"2026091912541429400_nlag096-B28","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1073\/pnas.1320611111","article-title":"Single cell-derived clonal analysis of human glioblastoma links functional and genomic heterogeneity","volume":"112","author":"Meyer","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026091912541429400_nlag096-B29","doi-asserted-by":"publisher","first-page":"100566","DOI":"10.1016\/j.esmoop.2022.100566","article-title":"Methylation subgroup and molecular heterogeneity is a hallmark of glioblastoma: implications for biopsy targeting, classification and therapy","volume":"7","author":"Gempt","year":"2022","journal-title":"ESMO Open"},{"key":"2026091912541429400_nlag096-B30","doi-asserted-by":"publisher","first-page":"5634","DOI":"10.3390\/ijms26125634","article-title":"Epigenetic alterations in glioblastoma multiforme as novel therapeutic targets: a scoping review","volume":"26","author":"Meleiro","year":"2025","journal-title":"Int J Mol Sci"},{"key":"2026091912541429400_nlag096-B31","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1016\/j.ccr.2011.11.005","article-title":"Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma","volume":"20","author":"Snuderl","year":"2011","journal-title":"Cancer Cell"},{"key":"2026091912541429400_nlag096-B32","doi-asserted-by":"publisher","first-page":"3041","DOI":"10.1073\/pnas.1114033109","article-title":"Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response","volume":"109","author":"Szerlip","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026091912541429400_nlag096-B33","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1158\/0008-5472.CAN-11-4069","article-title":"Receptor tyrosine kinase genes amplified in glioblastoma exhibit a mutual exclusivity in variable proportions reflective of individual tumor heterogeneity","volume":"72","author":"Little","year":"2012","journal-title":"Cancer Res"},{"key":"2026091912541429400_nlag096-B34","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/S0002-9440(10)61750-6","article-title":"Glioma classification: a molecular reappraisal","volume":"159","author":"Louis","year":"2001","journal-title":"Am J Pathol"},{"key":"2026091912541429400_nlag096-B35","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.2353\/ajpath.2007.070011","article-title":"Genetic pathways to primary and secondary glioblastoma","volume":"170","author":"Ohgaki","year":"2007","journal-title":"Am J Pathol"},{"key":"2026091912541429400_nlag096-B36","doi-asserted-by":"publisher","first-page":"6892","DOI":"10.1158\/0008-5472.CAN-04-1337","article-title":"Genetic pathways to glioblastoma: a population-based study","volume":"64","author":"Ohgaki","year":"2004","journal-title":"Cancer Res"},{"key":"2026091912541429400_nlag096-B37","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1038\/s41591-018-0156-x","article-title":"The DNA methylation landscape of glioblastoma disease progression shows extensive heterogeneity in time and space","volume":"24","author":"Klughammer","year":"2018","journal-title":"Nat Med"},{"key":"2026091912541429400_nlag096-B38","first-page":"1","volume-title":"Semin Cell Dev Biol","author":"Whittle","year":"2025"},{"key":"2026091912541429400_nlag096-B39","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s40478-024-01769-0","article-title":"Spatial transcriptomics reveals segregation of tumor cell states in glioblastoma and marked immunosuppression within the perinecrotic niche","volume":"12","author":"Liu","year":"2024","journal-title":"Acta Neuropathol Commun"},{"key":"2026091912541429400_nlag096-B40","doi-asserted-by":"publisher","first-page":"2899","DOI":"10.1016\/j.cell.2022.06.054","article-title":"Glioblastoma hijacks neuronal mechanisms for brain invasion","volume":"185","author":"Venkataramani","year":"2022","journal-title":"Cell"},{"key":"2026091912541429400_nlag096-B41","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1215\/15228517-2009-001","article-title":"Identification of regions correlating MGMT promoter methylation and gene expression in glioblastomas","volume":"11","author":"Everhard","year":"2009","journal-title":"Neuro Oncol"},{"key":"2026091912541429400_nlag096-B42","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1126\/science.1239947","article-title":"Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma","volume":"343","author":"Johnson","year":"2014","journal-title":"Science"},{"key":"2026091912541429400_nlag096-B43","doi-asserted-by":"publisher","first-page":"e64090","DOI":"10.7554\/eLife.64090","article-title":"Single-cell chromatin accessibility profiling of glioblastoma identifies an invasive cancer stem cell population associated with lower survival","volume":"10","author":"Guilhamon","year":"2021","journal-title":"Elife."},{"key":"2026091912541429400_nlag096-B44","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1007\/s11033-024-09433-5","article-title":"Human umbilical cord mesenchymal stem cell-derived exosomes alleviate the severity of experimental autoimmune encephalomyelitis and enhance lag-3 expression on foxp3+ CD4+ T cells","volume":"51","author":"Mohammadzadeh","year":"2024","journal-title":"Mol Biol Rep"},{"key":"2026091912541429400_nlag096-B45","doi-asserted-by":"publisher","first-page":"2828","DOI":"10.1093\/neuonc\/noaf169","article-title":"BRD2 bromodomain-mediated regulation of cell state plasticity modulates therapy response in glioblastoma","volume":"27","author":"Vadla","year":"2025","journal-title":"Neuro Oncol"},{"key":"2026091912541429400_nlag096-B46","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/s41698-024-00718-3","article-title":"Comparison of DNA methylation based classification models for precision diagnostics of central nervous system tumors","volume":"8","author":"Tran","year":"2024","journal-title":"NPJ Precis Oncol"},{"key":"2026091912541429400_nlag096-B47","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1111\/nan.12610","article-title":"Brain tumour diagnostics using a DNA methylation-based classifier as a diagnostic support tool","volume":"46","author":"Priesterbach-Ackley","year":"2020","journal-title":"Neuropathology Appl Neurobiol"},{"key":"2026091912541429400_nlag096-B48","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s40478-019-0668-8","article-title":"Methylation array profiling of adult brain tumours: diagnostic outcomes in a large, single centre","volume":"7","author":"Jaunmuktane","year":"2019","journal-title":"Acta Neuropathol Commun"},{"key":"2026091912541429400_nlag096-B49","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s00401-018-1879-y","article-title":"Practical implementation of DNA methylation and copy-number-based CNS tumor diagnostics: the Heidelberg experience","volume":"136","author":"Capper","year":"2018","journal-title":"Acta Neuropathol"},{"key":"2026091912541429400_nlag096-B50","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1007\/s00401-018-1913-0","article-title":"cIMPACT-NOW update 3: recommended diagnostic criteria for \u201cdiffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV","volume":"136","author":"Brat","year":"2018","journal-title":"Acta Neuropathol"},{"key":"2026091912541429400_nlag096-B51","doi-asserted-by":"publisher","first-page":"958146","DOI":"10.3389\/fphar.2022.958146","article-title":"Emerging role of different DNA methyltransferases in the pathogenesis of cancer","volume":"13","author":"Liu","year":"2022","journal-title":"Front Pharmacol"},{"key":"2026091912541429400_nlag096-B52","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/978-3-031-11454-0_3","article-title":"Domain structure of the DNMT1, DNMT3a, and DNMT3b DNA methyltransferases","volume":"1389","author":"Tajima","year":"2022","journal-title":"Adv Exp Med Biol"},{"key":"2026091912541429400_nlag096-B53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40364-017-0081-z","article-title":"DNA methyltransferases and their roles in tumorigenesis","volume":"5","author":"Zhang","year":"2017","journal-title":"Biomark Res"},{"key":"2026091912541429400_nlag096-B54","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1093\/bfgp\/elw019","article-title":"DNA methylation in adult diffuse gliomas","volume":"15","author":"LeBlanc","year":"2016","journal-title":"Brief Funct Genomics"},{"key":"2026091912541429400_nlag096-B55","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1101\/gad.212662.112","article-title":"Widespread resetting of DNA methylation in glioblastoma-initiating cells suppresses malignant cellular behavior in a lineage-dependent manner","volume":"27","author":"Stricker","year":"2013","journal-title":"Genes Dev"},{"key":"2026091912541429400_nlag096-B56","doi-asserted-by":"publisher","first-page":"118255","DOI":"10.1016\/j.ejmech.2025.118255","article-title":"DNMT1 drives glioma progression and modulates therapy response: a novel therapeutic target","volume":"301","author":"Armoundas","year":"2026","journal-title":"Eur J Med Chem"},{"key":"2026091912541429400_nlag096-B57","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.3390\/cells13141209","article-title":"Targeting DNA methylation machinery in pediatric solid tumors","volume":"13","author":"Cristalli","year":"2024","journal-title":"Cells"},{"key":"2026091912541429400_nlag096-B58","doi-asserted-by":"publisher","first-page":"e182","DOI":"10.1038\/emm.2015.57","article-title":"DNMT1 mediates chemosensitivity by reducing methylation of miRNA-20a promoter in glioma cells","volume":"47","author":"Zhou","year":"2015","journal-title":"Exp Mol Med"},{"key":"2026091912541429400_nlag096-B59","doi-asserted-by":"publisher","first-page":"e8","DOI":"10.1038\/cddis.2009.7","article-title":"Impact of the DNA methyltransferases expression on the methylation status of apoptosis-associated genes in glioblastoma multiforme","volume":"1","author":"Hervouet","year":"2010","journal-title":"Cell Death Dis"},{"key":"2026091912541429400_nlag096-B60","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s40478-024-01750-x","article-title":"DNA hypomethylator phenotype reprograms glutamatergic network in receptor tyrosine kinase gene-mutated glioblastoma","volume":"12","author":"Harachi","year":"2024","journal-title":"Acta Neuropathol Commun"},{"key":"2026091912541429400_nlag096-B61","doi-asserted-by":"publisher","first-page":"7066","DOI":"10.1007\/s12035-024-04041-7","article-title":"Downregulating DNA methyltransferase 3B by suppressing the PI3K\/Akt signaling pathway enhances the chemosensitivity of glioblastoma to temozolomide","volume":"61","author":"Kan","year":"2024","journal-title":"Mol Neurobiol"},{"key":"2026091912541429400_nlag096-B62","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.3390\/biom14091117","article-title":"The role of DNMT methyltransferases and TET dioxygenases in the maintenance of the DNA methylation level","volume":"14","author":"Davletgildeeva","year":"2024","journal-title":"Biomolecules"},{"key":"2026091912541429400_nlag096-B63","doi-asserted-by":"publisher","first-page":"100929","DOI":"10.1016\/j.neo.2023.100929","article-title":"Downregulation of MGMT expression by targeted editing of DNA methylation enhances temozolomide sensitivity in glioblastoma","volume":"44","author":"Han","year":"2023","journal-title":"Neoplasia"},{"key":"2026091912541429400_nlag096-B64","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1101\/gad.2037511","article-title":"CpG islands and the regulation of transcription","volume":"25","author":"Deaton","year":"2011","journal-title":"Genes Dev"},{"key":"2026091912541429400_nlag096-B65","doi-asserted-by":"publisher","first-page":"989985","DOI":"10.3389\/fgene.2022.989985","article-title":"Regulatory pattern of abnormal promoter CpG island methylation in the glioblastoma multiforme classification","volume":"13","author":"Wang","year":"2022","journal-title":"Front Genet"},{"key":"2026091912541429400_nlag096-B66","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.4161\/15592294.2014.983361","article-title":"RASSF6 exhibits promoter hypermethylation in metastatic melanoma and inhibits invasion in melanoma cells","volume":"9","author":"Mezzanotte","year":"2014","journal-title":"Epigenetics"},{"key":"2026091912541429400_nlag096-B67","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1093\/neuonc\/nox183","article-title":"Glioma CpG island methylator phenotype (G-CIMP): biological and clinical implications","volume":"20","author":"Malta","year":"2018","journal-title":"Neuro Oncol"},{"key":"2026091912541429400_nlag096-B68","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/S1470-2045(25)00705-3","article-title":"20 years of the Stupp protocol: confronting stagnation in glioblastoma therapy","volume":"27","author":"Khasraw","year":"2026","journal-title":"Lancet Oncol"},{"key":"2026091912541429400_nlag096-B69","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1093\/neuonc\/noy132","article-title":"MGMT promoter methylation status testing to guide therapy for glioblastoma: refining the approach based on emerging evidence and current challenges","volume":"21","author":"Mansouri","year":"2019","journal-title":"Neuro Oncol"},{"key":"2026091912541429400_nlag096-B70","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.trecan.2020.02.010","article-title":"MGMT status as a clinical biomarker in glioblastoma","volume":"6","author":"Butler","year":"2020","journal-title":"Trends Cancer"},{"key":"2026091912541429400_nlag096-B71","doi-asserted-by":"publisher","first-page":"157","DOI":"10.11648\/j.ijcocr.20251004.15","article-title":"Radiotherapy-induced skin injuries (RISIs): mechanisms and therapeutic approaches","volume":"10","author":"Charkhian","year":"2025","journal-title":"Int J Clin Oncol Cancer Res"},{"key":"2026091912541429400_nlag096-B72","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1093\/neuonc\/noae108","article-title":"No benefit from TMZ treatment in glioblastoma with truly unmethylated MGMT promoter: reanalysis of the CE. 6 and the pooled Nordic\/NOA-08 trials in elderly glioblastoma patients","volume":"26","author":"Hegi","year":"2024","journal-title":"Neuro Oncol"},{"key":"2026091912541429400_nlag096-B73","doi-asserted-by":"publisher","DOI":"10.18103\/mra.v13i9.6944","article-title":"Novel strategies for improved treatment of O6-methylguanine-DNA methyltransferase promoter-methylated glioma","volume":"13","author":"Vasquez","year":"2025","journal-title":"Med Res Arch"},{"key":"2026091912541429400_nlag096-B74","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.celrep.2018.03.107","article-title":"A distinct DNA methylation shift in a subset of glioma CpG island methylator phenotypes during tumor recurrence","volume":"23","author":"de Souza","year":"2018","journal-title":"Cell Rep"},{"key":"2026091912541429400_nlag096-B75","doi-asserted-by":"publisher","first-page":"102833","DOI":"10.1016\/j.legalmed.2026.102833","article-title":"Somatic mutations from pathogenesis to forensic medicine: opportunities, challenges, and future directions","volume":"82","author":"Charkhian","year":"2026","journal-title":"Leg Med (Tokyo)"},{"key":"2026091912541429400_nlag096-B76","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1038\/s41588-021-00927-7","article-title":"Epigenetic encoding, heritability and plasticity of glioma transcriptional cell states","volume":"53","author":"Chaligne","year":"2021","journal-title":"Nat Genet"},{"key":"2026091912541429400_nlag096-B77","doi-asserted-by":"publisher","first-page":"11780","DOI":"10.3390\/ijms252111780","article-title":"5-hydroxymethylcytosine: far beyond the intermediate of DNA demethylation","volume":"25","author":"Zheng","year":"2024","journal-title":"Int J Mol Sci"},{"key":"2026091912541429400_nlag096-B78","doi-asserted-by":"publisher","first-page":"744990","DOI":"10.3389\/fcell.2021.744990","article-title":"Deoxyribonucleic acid 5-hydroxymethylation in cell-free deoxyribonucleic acid, a novel cancer biomarker in the era of precision medicine","volume":"9","author":"Xu","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"2026091912541429400_nlag096-B79","doi-asserted-by":"publisher","first-page":"e41036","DOI":"10.1371\/journal.pone.0041036","article-title":"Decreased 5-hydroxymethylcytosine is associated with neural progenitor phenotype in normal brain and shorter survival in malignant glioma","volume":"7","author":"Orr","year":"2012","journal-title":"PLoS One"},{"key":"2026091912541429400_nlag096-B80","doi-asserted-by":"publisher","first-page":"832","DOI":"10.7150\/jca.12010","article-title":"Genetic characterization of ten-eleven-translocation methylcytosine dioxygenase alterations in human glioma","volume":"6","author":"Kraus","year":"2015","journal-title":"J Cancer"},{"key":"2026091912541429400_nlag096-B81","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1007\/s00401-018-1821-3","article-title":"5-Hydroxymethylcytosine preferentially targets genes upregulated in isocitrate dehydrogenase 1 mutant high-grade glioma","volume":"135","author":"Glowacka","year":"2018","journal-title":"Acta Neuropathol"},{"key":"2026091912541429400_nlag096-B82","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/s11910-013-0345-4","article-title":"IDH1 and IDH2 mutations in gliomas","volume":"13","author":"Cohen","year":"2013","journal-title":"Curr Neurol Neurosci Rep"},{"key":"2026091912541429400_nlag096-B83","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.trecan.2017.12.005","article-title":"Metabolism, activity, and targeting of D-and L-2-hydroxyglutarates","volume":"4","author":"Ye","year":"2018","journal-title":"Trends Cancer"},{"key":"2026091912541429400_nlag096-B84","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/nature10866","article-title":"IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype","volume":"483","author":"Turcan","year":"2012","journal-title":"Nature"},{"key":"2026091912541429400_nlag096-B85","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/s41588-017-0001-z","article-title":"Mutant-IDH1-dependent chromatin state reprogramming, reversibility, and persistence","volume":"50","author":"Turcan","year":"2018","journal-title":"Nat Genet"},{"key":"2026091912541429400_nlag096-B86","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1158\/0008-5472.CAN-23-2093","article-title":"The epigenetic evolution of glioma is determined by the IDH1 mutation status and treatment regimen","volume":"84","author":"Malta","year":"2024","journal-title":"Cancer Res"},{"key":"2026091912541429400_nlag096-B87","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3892\/or.2023.8580","article-title":"RB1\u2011promoter methylation in glioblastoma: a rare event in glioblastoma","volume":"50","author":"Urbschat","year":"2023","journal-title":"Oncol Rep"},{"key":"2026091912541429400_nlag096-B88","doi-asserted-by":"publisher","first-page":"vdaa126","DOI":"10.1093\/noajnl\/vdaa126","article-title":"Prognostic impact of CDKN2A\/B deletion, TERT mutation, and EGFR amplification on histological and molecular IDH-wildtype glioblastoma","volume":"2","author":"Ma","year":"2020","journal-title":"Neurooncol Adv"},{"key":"2026091912541429400_nlag096-B89","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1093\/neuonc\/noac205","article-title":"Translational significance of CDKN2A\/B homozygous deletion in isocitrate dehydrogenase-mutant astrocytoma","volume":"25","author":"Fortin Ensign","year":"2023","journal-title":"Neuro Oncol"},{"key":"2026091912541429400_nlag096-B90","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/s41374-021-00694-3","article-title":"Sporadic and Lynch syndrome-associated mismatch repair-deficient brain tumors","volume":"102","author":"Kim","year":"2022","journal-title":"Lab Invest"},{"key":"2026091912541429400_nlag096-B91","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/1480-9222-14-5","article-title":"A reinvestigation of somatic hypermethylation at the PTEN CpG island in cancer cell lines","volume":"14","author":"Hesson","year":"2012","journal-title":"Biol Proced Online"},{"key":"2026091912541429400_nlag096-B92","doi-asserted-by":"publisher","first-page":"297","DOI":"10.3390\/cancers10090297","article-title":"The p53 pathway in glioblastoma","volume":"10","author":"Zhang","year":"2018","journal-title":"Cancers (Basel)"},{"key":"2026091912541429400_nlag096-B93","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1089\/dna.2013.2201","article-title":"TP53 promoter methylation in primary glioblastoma: relationship with TP53 mRNA and protein expression and mutation status","volume":"33","author":"Jesionek-Kupnicka","year":"2014","journal-title":"DNA Cell Biol"},{"key":"2026091912541429400_nlag096-B94","doi-asserted-by":"publisher","first-page":"3946320241250294","DOI":"10.1177\/03946320241250294","article-title":"Clinical role of NDRG2-based methylation status on survival pattern of glioblastoma","volume":"38","author":"Swellam","year":"2024","journal-title":"Int J Immunopathol Pharmacol"},{"key":"2026091912541429400_nlag096-B95","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1186\/s12885-024-12345-z","article-title":"mRNA markers for survival prediction in glioblastoma multiforme patients: a systematic review with bioinformatic analyses","volume":"24","author":"Azimi","year":"2024","journal-title":"BMC Cancer"},{"key":"2026091912541429400_nlag096-B96","doi-asserted-by":"publisher","first-page":"184","DOI":"10.3390\/cells10010184","article-title":"Hippo signaling pathway in gliomas","volume":"10","author":"Masliantsev","year":"2021","journal-title":"Cells"},{"key":"2026091912541429400_nlag096-B97","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1093\/neuonc\/noae213","article-title":"Updated EANO guideline on rational molecular testing of gliomas, glioneuronal, and neuronal tumors in adults for targeted therapy selection\u2014update 1","volume":"27","author":"Van Den Bent","year":"2025","journal-title":"Neuro Oncol"},{"key":"2026091912541429400_nlag096-B98","doi-asserted-by":"publisher","first-page":"586581","DOI":"10.3389\/fcell.2020.586581","article-title":"Hypermethylation of LATS2 promoter and its prognostic value in IDH-mutated low-grade gliomas","volume":"8","author":"Gu","year":"2020","journal-title":"Front Cell Dev Biol"},{"key":"2026091912541429400_nlag096-B99","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1101\/gr.164707.113","article-title":"Recurrent epimutations activate gene body promoters in primary glioblastoma","volume":"24","author":"Nagarajan","year":"2014","journal-title":"Genome Res"},{"key":"2026091912541429400_nlag096-B100","doi-asserted-by":"publisher","first-page":"4644","DOI":"10.1002\/cam4.4016","article-title":"Integrative analysis of TP73 profile prognostic significance in WHO grade II\/III glioma","volume":"10","author":"Chen","year":"2021","journal-title":"Cancer Med"},{"key":"2026091912541429400_nlag096-B101","doi-asserted-by":"publisher","first-page":"26637","DOI":"10.18632\/oncotarget.15789","article-title":"CBX7 is a glioma prognostic marker and induces G1\/S arrest via the silencing of CCNE1","volume":"8","author":"Yu","year":"2017","journal-title":"Oncotarget"},{"key":"2026091912541429400_nlag096-B102","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41420-025-02362-7","article-title":"Chromobox protein homolog 7 suppresses the stem-like phenotype of glioblastoma cells by regulating the myosin heavy chain 9-NF-\u03baB signaling pathway","volume":"11","author":"Ni","year":"2025","journal-title":"Cell Death Discov"},{"key":"2026091912541429400_nlag096-B103","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1093\/neuonc\/noad100","article-title":"Molecular diagnostic tools for the World Health Organization (WHO) 2021 classification of gliomas, glioneuronal and neuronal tumors; an EANO guideline","volume":"25","author":"Sahm","year":"2023","journal-title":"Neuro Oncol"},{"key":"2026091912541429400_nlag096-B104","doi-asserted-by":"publisher","first-page":"98348","DOI":"10.18632\/oncotarget.21311","article-title":"The EZH2 inhibitor GSK343 suppresses cancer stem-like phenotypes and reverses mesenchymal transition in glioma cells","volume":"8","author":"Yu","year":"2017","journal-title":"Oncotarget"},{"key":"2026091912541429400_nlag096-B105","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1038\/aps.2017.7","article-title":"Structure of the PRC2 complex and application to drug discovery","volume":"38","author":"Shi","year":"2017","journal-title":"Acta Pharmacol Sin"},{"key":"2026091912541429400_nlag096-B106","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1093\/neuonc\/noq190","article-title":"DNA hypermethylation profiles associated with glioma subtypes and EZH2 and IGFBP2 mRNA expression","volume":"13","author":"Zheng","year":"2011","journal-title":"Neuro Oncol"},{"key":"2026091912541429400_nlag096-B107","doi-asserted-by":"publisher","first-page":"62","DOI":"10.5301\/ijbm.5000293","article-title":"Prognostic role of EZH2 in gliomas: a meta-analysis","volume":"33","author":"Pyo","year":"2018","journal-title":"Int J Biol Markers"},{"key":"2026091912541429400_nlag096-B108","doi-asserted-by":"publisher","first-page":"2485","DOI":"10.1038\/s41467-021-22720-0","article-title":"A pan-cancer analysis of CpG island gene regulation reveals extensive plasticity within Polycomb target genes","volume":"12","author":"Zheng","year":"2021","journal-title":"Nat Commun"},{"key":"2026091912541429400_nlag096-B109","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s11060-024-04726-y","article-title":"TRIM37 interacts with EZH2 to epigenetically suppress PTCH1 and regulate stemness in glioma stem cells through sonic hedgehog pathway","volume":"169","author":"Cai","year":"2024","journal-title":"J Neurooncol"},{"key":"2026091912541429400_nlag096-B110","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1038\/s41388-022-02570-w","article-title":"EZH2 interacts with HP1BP3 to epigenetically activate WNT7B that promotes temozolomide resistance in glioblastoma","volume":"42","author":"Yu","year":"2023","journal-title":"Oncogene"},{"key":"2026091912541429400_nlag096-B111","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1093\/brain\/awab020","article-title":"De novo purine biosynthesis is a major driver of chemoresistance in glioblastoma","volume":"144","author":"Shireman","year":"2021","journal-title":"Brain"},{"key":"2026091912541429400_nlag096-B112","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1038\/s41467-021-21204-5","article-title":"PRMT5 inhibition disrupts splicing and stemness in glioblastoma","volume":"12","author":"Sachamitr","year":"2021","journal-title":"Nat Commun"},{"key":"2026091912541429400_nlag096-B113","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.1158\/1541-7786.MCR-21-0093","article-title":"Epigenetic regulation of Fanconi anemia genes implicates PRMT5 blockage as a strategy for tumor chemosensitization","volume":"19","author":"Du","year":"2021","journal-title":"Mol Cancer Res"},{"key":"2026091912541429400_nlag096-B114","doi-asserted-by":"publisher","first-page":"2956","DOI":"10.1093\/nar\/gkaa065","article-title":"PRMT5-mediated histone arginine methylation antagonizes transcriptional repression by Polycomb complex PRC2","volume":"48","author":"Liu","year":"2020","journal-title":"Nucleic Acids Res"},{"key":"2026091912541429400_nlag096-B115","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1007\/s00018-015-1847-9","article-title":"The PRMT5 arginine methyltransferase: many roles in development, cancer and beyond","volume":"72","author":"Stopa","year":"2015","journal-title":"Cell Mol Life Sci"},{"key":"2026091912541429400_nlag096-B116","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s42764-023-00111-7","article-title":"The role of protein arginine methylation 5 in DNA damage repair and cancer therapy","volume":"4","author":"Gao","year":"2023","journal-title":"Genome Instab Dis"},{"key":"2026091912541429400_nlag096-B117","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1158\/0008-5472.CAN-13-0884","article-title":"Genetic validation of the protein arginine methyltransferase PRMT5 as a candidate therapeutic target in glioblastoma","volume":"74","author":"Yan","year":"2014","journal-title":"Cancer Res"},{"key":"2026091912541429400_nlag096-B118","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1093\/neuonc\/nox206","article-title":"PRMT5 as a druggable target for glioblastoma therapy","volume":"20","author":"Banasavadi-Siddegowda","year":"2018","journal-title":"Neuro Oncol"},{"key":"2026091912541429400_nlag096-B119","doi-asserted-by":"publisher","first-page":"487","DOI":"10.3389\/fimmu.2015.00487","article-title":"Functional role of G9a histone methyltransferase in cancer","volume":"6","author":"Casciello","year":"2015","journal-title":"Front Immunol"},{"key":"2026091912541429400_nlag096-B120","doi-asserted-by":"publisher","first-page":"11292","DOI":"10.3390\/ijms222011292","article-title":"EHMT2\/G9a as an epigenetic target in pediatric and adult brain tumors","volume":"22","author":"Souza","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2026091912541429400_nlag096-B121","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1158\/0008-5472.CAN-21-2218","article-title":"Combined inhibition of G9a and EZH2 suppresses tumor growth via synergistic induction of IL24-mediated apoptosis","volume":"82","author":"Casciello","year":"2022","journal-title":"Cancer Res"},{"key":"2026091912541429400_nlag096-B122","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.3389\/fphar.2018.01271","article-title":"Pre-treatment or post-treatment of human glioma cells with BIX01294, the inhibitor of histone methyltransferase G9a, sensitizes cells to temozolomide","volume":"9","author":"Ciechomska","year":"2018","journal-title":"Front Pharmacol"},{"key":"2026091912541429400_nlag096-B123","doi-asserted-by":"publisher","first-page":"38723","DOI":"10.1038\/srep38723","article-title":"IX01294, an inhibitor of histone methyltransferase, induces autophagy-dependent differentiation of glioma stem-like cells","volume":"6","author":"Ciechomska","year":"2016","journal-title":"Sci Rep"},{"key":"2026091912541429400_nlag096-B124","doi-asserted-by":"publisher","first-page":"6576","DOI":"10.1093\/nar\/gky449","article-title":"Methylation of hypoxia-inducible factor (HIF)-1\u03b1 by G9a\/GLP inhibits HIF-1 transcriptional activity and cell migration","volume":"46","author":"Bao","year":"2018","journal-title":"Nucleic Acids Res"},{"key":"2026091912541429400_nlag096-B125","doi-asserted-by":"publisher","first-page":"24518","DOI":"10.18632\/oncotarget.15543","article-title":"Epigenetic therapy with inhibitors of histone methylation suppresses DNA damage signaling and increases glioma cell radiosensitivity","volume":"8","author":"Gursoy-Yuzugullu","year":"2017","journal-title":"Oncotarget"},{"key":"2026091912541429400_nlag096-B126","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1007\/s12032-022-01683-2","article-title":"Unique combinations of epigenetic modifiers synergistically impair the viability of the U87 glioblastoma cell line while exhibiting minor or moderate effects on normal stem cell growth","volume":"39","author":"Alexanian","year":"2022","journal-title":"Med Oncol"},{"key":"2026091912541429400_nlag096-B127","doi-asserted-by":"publisher","first-page":"a018713","DOI":"10.1101\/cshperspect.a018713","article-title":"Erasers of histone acetylation: the histone deacetylase enzymes","volume":"6","author":"Seto","year":"2014","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"2026091912541429400_nlag096-B128","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/sj.cr.7310149","article-title":"HDACs, histone deacetylation and gene transcription: from molecular biology to cancer therapeutics","volume":"17","author":"Gallinari","year":"2007","journal-title":"Cell Res"},{"key":"2026091912541429400_nlag096-B129","doi-asserted-by":"crossref","first-page":"e149232","DOI":"10.1172\/jci.insight.149232","article-title":"Nonredundant, isoform-specific roles of HDAC1 in glioma stem cells","volume":"6","author":"Cascio","year":"2021","journal-title":"JCI Insight"},{"key":"2026091912541429400_nlag096-B130","doi-asserted-by":"publisher","first-page":"3183","DOI":"10.1096\/fj.13-241760","article-title":"A central role for G9a and EZH2 in the epigenetic silencing of cyclooxygenase-2 in idiopathic pulmonary fibrosis","volume":"28","author":"Coward","year":"2014","journal-title":"FASEB J"},{"key":"2026091912541429400_nlag096-B131","doi-asserted-by":"publisher","first-page":"840759","DOI":"10.3389\/fcell.2022.840759","article-title":"Comprehensive analysis of the differential expression and prognostic value of histone deacetylases in glioma","volume":"10","author":"Li","year":"2022","journal-title":"Front Cell Dev Biol"},{"key":"2026091912541429400_nlag096-B132","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s40364-025-00788-w","article-title":"Epigenetic regulation of histone modifications in glioblastoma: recent advances and therapeutic insights","volume":"13","author":"Zhang","year":"2025","journal-title":"Biomark Res"},{"key":"2026091912541429400_nlag096-B133","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1038\/cdd.2011.95","article-title":"HIF-1\u03b1 is critical for hypoxia-mediated maintenance of glioblastoma stem cells by activating notch signaling pathway","volume":"19","author":"Qiang","year":"2012","journal-title":"Cell Death Differ"},{"key":"2026091912541429400_nlag096-B134","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41419-022-04751-7","article-title":"Class I HDAC overexpression promotes temozolomide resistance in glioma cells by regulating RAD18 expression","volume":"13","author":"Hanisch","year":"2022","journal-title":"Cell Death Dis"},{"key":"2026091912541429400_nlag096-B135","author":"Gurrea Rubio","year":"2012"},{"key":"2026091912541429400_nlag096-B136","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1186\/1471-2407-8-243","article-title":"Differential expression of 12 histone deacetylase (HDAC) genes in astrocytomas and normal brain tissue: class II and IV are hypoexpressed in glioblastomas","volume":"8","author":"Lucio-Eterovic","year":"2008","journal-title":"BMC Cancer"},{"key":"2026091912541429400_nlag096-B137","doi-asserted-by":"publisher","first-page":"2631","DOI":"10.3390\/biomedicines12112631","article-title":"The role of HDAC6 in glioblastoma multiforme: a new avenue to therapeutic interventions?","volume":"12","author":"Spallotta","year":"2024","journal-title":"Biomedicines"},{"key":"2026091912541429400_nlag096-B138","doi-asserted-by":"publisher","first-page":"576946","DOI":"10.3389\/fcell.2020.576946","article-title":"The roles of histone deacetylases and their inhibitors in cancer therapy","volume":"8","author":"Li","year":"2020","journal-title":"Front Cell Dev Biol"},{"key":"2026091912541429400_nlag096-B139","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1002\/stem.89","article-title":"DNER, an epigenetically modulated gene, regulates glioblastoma-derived neurosphere cell differentiation and tumor propagation","volume":"27","author":"Sun","year":"2009","journal-title":"Stem Cells"},{"key":"2026091912541429400_nlag096-B140","doi-asserted-by":"publisher","first-page":"8084","DOI":"10.3390\/ijms23158084","article-title":"HDAC class I inhibitor domatinostat preferentially targets glioma stem cells over their differentiated progeny","volume":"23","author":"Nakagawa-Saito","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2026091912541429400_nlag096-B141","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1093\/neuonc\/nox161","article-title":"Phase I\/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of alliance N0874\/ABTC 02","volume":"20","author":"Galanis","year":"2018","journal-title":"Neuro Oncol"},{"key":"2026091912541429400_nlag096-B142","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3390\/epigenomes2010005","article-title":"Panobinostat potentiates temozolomide effects and reverses epithelial-mesenchymal transition in glioblastoma cells","volume":"2","author":"Urdiciain","year":"2018","journal-title":"Epigenomes"},{"key":"2026091912541429400_nlag096-B143","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/j.ijrobp.2015.04.038","article-title":"A phase 2 study of concurrent radiation therapy, temozolomide, and the histone deacetylase inhibitor valproic acid for patients with glioblastoma","volume":"92","author":"Krauze","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026091912541429400_nlag096-B144","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s13046-020-01643-6","article-title":"The application of histone deacetylases inhibitors in glioblastoma","volume":"39","author":"Chen","year":"2020","journal-title":"J Exp Clin Cancer Res"},{"key":"2026091912541429400_nlag096-B145","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1093\/neuonc\/nor017","article-title":"A phase I\/II trial of the histone deacetylase inhibitor romidepsin for adults with recurrent malignant glioma: North American Brain Tumor Consortium Study 03-03","volume":"13","author":"Iwamoto","year":"2011","journal-title":"Neuro Oncol"},{"key":"2026091912541429400_nlag096-B146","doi-asserted-by":"publisher","first-page":"6731","DOI":"10.21873\/anticanres.13888","article-title":"Temozolomide-resistant glioblastoma depends on HDAC6 activity through regulation of DNA mismatch repair","volume":"39","author":"Kim","year":"2019","journal-title":"Anticancer Res"},{"key":"2026091912541429400_nlag096-B147","doi-asserted-by":"crossref","first-page":"e167081","DOI":"10.1172\/jci.insight.167081","article-title":"Quisinostat is a brain-penetrant radiosensitizer in glioblastoma","volume":"8","author":"Cascio","year":"2023","journal-title":"JCI Insight"},{"key":"2026091912541429400_nlag096-B148","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.21873\/anticanres.16258","article-title":"Givinostat inhibition of sp1-dependent MGMT expression sensitizes glioma stem cells to temozolomide","volume":"43","author":"Nakagawa-Saito","year":"2023","journal-title":"Anticancer Res"},{"key":"2026091912541429400_nlag096-B149","first-page":"615","article-title":"Mechanisms and clinical significance of histone deacetylase inhibitors: epigenetic glioblastoma therapy","volume":"35","author":"Lee","year":"2015","journal-title":"Anticancer Res"},{"key":"2026091912541429400_nlag096-B150","doi-asserted-by":"publisher","first-page":"942","DOI":"10.3390\/tomography9030077","article-title":"Mutant isocitrate dehydrogenase 1 expression enhances response of gliomas to the histone deacetylase inhibitor belinostat","volume":"9","author":"Chang","year":"2023","journal-title":"Tomography"},{"key":"2026091912541429400_nlag096-B151","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1056\/NEJMoa043331","article-title":"MGMT gene silencing and benefit from temozolomide in glioblastoma","volume":"352","author":"Hegi","year":"2005","journal-title":"N Engl J Med"},{"key":"2026091912541429400_nlag096-B152","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.bbcan.2011.12.004","article-title":"O6-Methylguanine-DNA methyltransferase in glioma therapy: promise and problems","volume":"1826","author":"Silber","year":"2012","journal-title":"Biochim Biophys Acta"},{"key":"2026091912541429400_nlag096-B153","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/S1470-2045(12)70164-X","article-title":"Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial","volume":"13","author":"Wick","year":"2012","journal-title":"Lancet Oncol"},{"key":"2026091912541429400_nlag096-B154","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1016\/S1470-2045(12)70265-6","article-title":"Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial","volume":"13","author":"Malmstr\u00f6m","year":"2012","journal-title":"Lancet Oncol"},{"key":"2026091912541429400_nlag096-B155","doi-asserted-by":"publisher","first-page":"e85102","DOI":"10.1371\/journal.pone.0085102","article-title":"The predictive but not prognostic value of MGMT promoter methylation status in elderly glioblastoma patients: a meta-analysis","volume":"9","author":"Yin","year":"2014","journal-title":"PLoS One"},{"key":"2026091912541429400_nlag096-B156","doi-asserted-by":"publisher","first-page":"354","DOI":"10.7150\/jca.63595","article-title":"Clinical strategies to manage adult glioblastoma patients without MGMT hypermethylation","volume":"13","author":"Liu","year":"2022","journal-title":"J Cancer"},{"key":"2026091912541429400_nlag096-B157","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1007\/s10147-014-0769-0","article-title":"A phase III study of radiation therapy (RT) and O6-benzylguanine\u2009+\u2009BCNU versus RT and BCNU alone and methylation status in newly diagnosed glioblastoma and gliosarcoma: Southwest Oncology Group (SWOG) study S0001","volume":"20","author":"Blumenthal","year":"2015","journal-title":"Int J Clin Oncol"},{"key":"2026091912541429400_nlag096-B158","doi-asserted-by":"publisher","first-page":"18577","DOI":"10.18632\/oncotarget.14612","article-title":"Advances in epigenetic glioblastoma therapy","volume":"8","author":"Lee","year":"2017","journal-title":"Oncotarget"},{"key":"2026091912541429400_nlag096-B159","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1093\/neuonc\/noy146","article-title":"Demethylation and epigenetic modification with 5-azacytidine reduces IDH1 mutant glioma growth in combination with temozolomide","volume":"21","author":"Yamashita","year":"2019","journal-title":"Neuro Oncol"},{"key":"2026091912541429400_nlag096-B160","doi-asserted-by":"publisher","first-page":"1704311","DOI":"10.3389\/fmolb.2025.1704311","article-title":"Niche-specific epigenetic interventions in the spatially heterogeneous glioblastoma microenvironmental landscape: strategies for radiotherapy enhancement","volume":"12","author":"Wang","year":"2025","journal-title":"Front Mol Biosci"},{"key":"2026091912541429400_nlag096-B161","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1158\/2767-9764.CRC-23-0566","article-title":"Epigenetic induction of cancer-testis antigens and endogenous retroviruses at single-cell level enhances immune recognition and response in glioma","volume":"4","author":"Lai","year":"2024","journal-title":"Cancer Res Commun"},{"key":"2026091912541429400_nlag096-B162","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1093\/neuonc\/noac107","article-title":"Decitabine increases neoantigen and cancer testis antigen expression to enhance T-cell\u2013mediated toxicity against glioblastoma","volume":"24","author":"Ma","year":"2022","journal-title":"Neuro Oncol"},{"key":"2026091912541429400_nlag096-B163","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s11060-023-04531-z","article-title":"dCas9\/CRISPR-based methylation of O-6-methylguanine-DNA methyltransferase enhances chemosensitivity to temozolomide in malignant glioma","volume":"166","author":"Zapanta Rinonos","year":"2024","journal-title":"J Neurooncol"},{"key":"2026091912541429400_nlag096-B164","doi-asserted-by":"publisher","first-page":"292","DOI":"10.3390\/cancers11030292","article-title":"Role of notch signaling pathway in glioblastoma pathogenesis","volume":"11","author":"Bazzoni","year":"2019","journal-title":"Cancers (Basel)"},{"key":"2026091912541429400_nlag096-B165","doi-asserted-by":"publisher","first-page":"602378","DOI":"10.3389\/fonc.2020.602378","article-title":"The epigenetics of glioma stem cells: a brief overview","volume":"10","author":"Valor","year":"2020","journal-title":"Front Oncol"},{"key":"2026091912541429400_nlag096-B166","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/nm.4036","article-title":"Targeting EZH2 in cancer","volume":"22","author":"Kim","year":"2016","journal-title":"Nat Med"},{"key":"2026091912541429400_nlag096-B167","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/s10637-023-01370-7","article-title":"Epigenetic modifiers either individually or in specific combinations impair viability of patient-derived glioblastoma cell line while exhibit moderate effect on normal stem cells growth","volume":"41","author":"Alexanian","year":"2023","journal-title":"Invest New Drugs"},{"key":"2026091912541429400_nlag096-B168","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3390\/ijtm5030027","article-title":"Exploiting synthetic lethality of PRMT5 for precision treatment of MTAP-deficient glioblastoma","volume":"5","author":"Nguyen","year":"2025","journal-title":"Int J Transl Med"},{"key":"2026091912541429400_nlag096-B169","doi-asserted-by":"publisher","first-page":"8594","DOI":"10.3390\/ijms21228594","article-title":"Mammalian PRC1 complexes: compositional complexity and diverse molecular mechanisms","volume":"21","author":"Geng","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2026091912541429400_nlag096-B170","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.18632\/aging.203912","article-title":"Expression profile and prognostic values of chromobox family members in human glioblastoma","volume":"14","author":"Li","year":"2022","journal-title":"Aging (Albany NY)"},{"key":"2026091912541429400_nlag096-B171","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s12915-020-0752-3","article-title":"Bivalent promoter hypermethylation in cancer is linked to the H327me3\/H3K4me3 ratio in embryonic stem cells","volume":"18","author":"Dunican","year":"2020","journal-title":"BMC Biol"},{"key":"2026091912541429400_nlag096-B172","doi-asserted-by":"publisher","first-page":"1144184","DOI":"10.3389\/fonc.2023.1144184","article-title":"The function of histone methylation and acetylation regulators in GBM pathophysiology","volume":"13","author":"McCornack","year":"2023","journal-title":"Front Oncol"},{"key":"2026091912541429400_nlag096-B173","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1158\/2159-8290.CD-20-1848","article-title":"Transcription elongation machinery is a druggable dependency and potentiates immunotherapy in glioblastoma stem cells","volume":"12","author":"Qiu","year":"2022","journal-title":"Cancer Discov"},{"key":"2026091912541429400_nlag096-B174","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/nature16490","article-title":"Insulator dysfunction and oncogene activation in IDH mutant gliomas","volume":"529","author":"Flavahan","year":"2016","journal-title":"Nature"},{"key":"2026091912541429400_nlag096-B175","doi-asserted-by":"publisher","first-page":"6130","DOI":"10.1038\/s41467-021-26297-6","article-title":"Comparative epigenetic analysis of tumour initiating cells and syngeneic EPSC-derived neural stem cells in glioblastoma","volume":"12","author":"Vinel","year":"2021","journal-title":"Nat Commun"},{"key":"2026091912541429400_nlag096-B176","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1101\/gad.349803.122","article-title":"WDR5 represents a therapeutically exploitable target for cancer stem cells in glioblastoma","volume":"37","author":"Mitchell","year":"2023","journal-title":"Genes Dev"},{"key":"2026091912541429400_nlag096-B177","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/s41420-025-02545-2","article-title":"Combined inhibition by PRMT5 and MAT2A demonstrates a strong synthetic lethality in MTAP homozygous-deficient glioma models","volume":"11","author":"Jiang","year":"2025","journal-title":"Cell Death Discov"},{"key":"2026091912541429400_nlag096-B178","doi-asserted-by":"publisher","first-page":"eabf3917","DOI":"10.1126\/scitranslmed.abf3917","article-title":"Glioblastoma stem cells reprogram chromatin in vivo to generate selective therapeutic dependencies on DPY30 and phosphodiesterases","volume":"14","author":"Dixit","year":"2022","journal-title":"Sci Transl Med"}],"container-title":["Journal of Neuropathology &amp; Experimental Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jnen\/advance-article-pdf\/doi\/10.1093\/jnen\/nlag096\/71236025\/nlag096.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jnen\/advance-article-pdf\/doi\/10.1093\/jnen\/nlag096\/71236025\/nlag096.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T16:54:21Z","timestamp":1789836861000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jnen\/advance-article\/doi\/10.1093\/jnen\/nlag096\/8818142"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,19]]},"references-count":178,"URL":"https:\/\/doi.org\/10.1093\/jnen\/nlag096","relation":{},"ISSN":["0022-3069","1554-6578"],"issn-type":[{"value":"0022-3069","type":"print"},{"value":"1554-6578","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,19]]},"article-number":"nlag096"}}